Boule Diagnostics AB (STU:8BD) Cyclically Adjusted PS Ratio: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8BD Boule Diagnostics AB STU:8BD
47 GF Score
Price €0.48
GF Value €0.89
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Boule Diagnostics AB  (STU:8BD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boule Diagnostics AB Cyclically Adjusted PS Ratio Related Terms


Boule Diagnostics AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Cyclically Adjusted PS Ratio Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 0.85 0.60 0.48 0.27

Boule Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.28 0.27 0.22 0.20

STU:8BD vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Boule Diagnostics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Cyclically Adjusted PS Ratio falls into.


STU:8BD
47GF Score
Boule Diagnostics AB STU:8BD
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boule Diagnostics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Boule Diagnostics AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.264/134.1100*134.1100
=0.264

Current CPI (Jun. 2026) = 134.1100.

Boule Diagnostics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.418 101.138 0.554
201612 0.379 102.022 0.498
201703 0.407 102.022 0.535
201706 0.413 102.752 0.539
201709 0.422 103.279 0.548
201712 0.382 103.793 0.494
201803 0.358 103.962 0.462
201806 0.384 104.875 0.491
201809 0.388 105.679 0.492
201812 0.345 105.912 0.437
201903 0.416 105.886 0.527
201906 0.411 106.742 0.516
201909 0.445 107.214 0.557
201912 0.455 107.766 0.566
202003 0.396 106.563 0.498
202006 0.314 107.498 0.392
202009 0.335 107.635 0.417
202012 0.301 108.296 0.373
202103 0.467 108.360 0.578
202106 0.387 108.928 0.476
202109 0.395 110.338 0.480
202112 0.553 112.486 0.659
202203 0.465 114.825 0.543
202206 0.458 118.384 0.519
202209 0.436 122.296 0.478
202212 0.420 126.365 0.446
202303 0.323 127.042 0.341
202306 0.323 129.407 0.335
202309 0.308 130.224 0.317
202312 0.347 131.912 0.353
202403 0.333 132.205 0.338
202406 0.303 132.716 0.306
202409 0.296 132.304 0.300
202412 0.325 132.987 0.328
202503 0.270 132.825 0.273
202506 0.309 133.699 0.310
202509 0.297 133.480 0.298
202512 0.284 133.390 0.286
202603 0.243 133.560 0.244
202606 0.264 134.110 0.264

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Boule Diagnostics AB (STU:8BD) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of €0.48 is trading 46.1% below its estimated GF Value™ of €0.89.

Key valuation signals for STU:8BD:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.89 vs. price of €0.48 (46.1% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the STU:8BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for STU:8BD

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.89
GF Value